Circulating Glucagon-like Peptide-1 (GLP-1) Inhibits Eating in Male Rats by Acting in the Hindbrain and Without Inducing Avoidance

Endocrinology

Volumn 155, Issue 5, 2014, Pages 1690-1699

  Punjabi, Mukesh ^a   Arnold, Myrtha ^a   Rüttimann, Elisabeth ^a   Graber, Mariana ^a   Geary, Nori ^a   Pacheco López, Gustavo ^a   Langhans, Wolfgang ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 9; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; SACCHARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA POSTREMA; ARTICLE; AVOIDANCE BEHAVIOR; CAVA VEIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EATING; MALE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; RAT; RHOMBENCEPHALON; WART VIRUS;

ANIMALS; APPETITE DEPRESSANTS; APPETITE REGULATION; APPETITE STIMULANTS; APPETITIVE BEHAVIOR; AREA POSTREMA; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM AGENTS; GLUCAGON-LIKE PEPTIDE 1; INFUSIONS, INTRAVENOUS; INFUSIONS, INTRAVENTRICULAR; MALE; NERVE TISSUE PROTEINS; NEURONS; PEPTIDE FRAGMENTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; RHOMBENCEPHALON; SIGNAL TRANSDUCTION;

EID: 84899420832     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1447     Document Type: Article

References (70)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157.
3. D'Alessio D, Lu W, Sun W, et al. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. Am J Physiol Regul Integr Comp Physiol. 2007;293(6):R2163-R2169.
4. Arnold M, Dai Y, Tso P, Langhans W. Meal-contingent intestinal lymph sampling from awake, unrestrained rats. Am J Physiol Regul Integr Comp Physiol. 2012;302(12):R1365-1371.
5. HassanM,Eskilsson A, Nilsson C, et al. In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera. Nucl Med Biol. 1999;26(4):413-420.
6. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucosedependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136(8):3585-3596.
7. Scott KA, Moran TH. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol. 2007;293(3):R983-R987.
8. Reidelberger RD, Haver AC, Apenteng BA, Anders KL, Steenson SM. Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats. Obesity (Silver Spring). 2011;19(1):121-127.
9. Bradley DP, Kulstad R, Schoeller DA. Exenatide and weight loss. Nutrition. 2010;26(3):243-249.
10. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes. 2001;50(11):2530-2539.
11. Gutzwiller JP, Göke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999;44(1):81-86.
12. Gutzwiller JP, Degen L, Heuss L, Beglinger C. Glucagon-like peptide 1 (GLP-1) and eating. Physiol Behav. 2004;82(1):17-19.
13. Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr. 2010;92(4): 810-817.
14. Torekov SS, Madsbad S, Holst JJ. Obesity-an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obes Rev. 2011;12(8):593-601.
15. Rüttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagonlike peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology. 2009;150(3):1174-1181.
16. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol. 1999;403(2):261-280.
17. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci. 1995;7(11):2294-2300.
18. Orskov C, Poulsen SS, Møller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes. 1996;45(6): 832-835.
19. Baumgartner I, Pacheco-López G, Rüttimann EB, et al. Hepaticportal vein infusions of glucagon-like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii, area postrema and central nucleus of the amygdala in rats. J Neuroendocrinol.2010;22(6):557-563.
20. Thiele TE, Van Dijk G, Campfield LA, et al. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol. 1997;272(2 Pt 2):R726-R730.
21. Rinaman L. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia.AmJ Physiol. 1999; 277(5 Pt 2):R1537-R1540.
22. Seeley RJ, Blake K, Rushing PA, et al. The role ofCNSglucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci. 2000;20(4):1616-1621.
23. McMahon LR, Wellman PJ. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol. 1998;274(1 Pt 2):R23-R29.
24. van Dijk G, Thiele TE. Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress. Neuropeptides. 1999;33(5):406-414.
25. Kinzig KP, D'Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci. 2002;22(23):10470-10476.
26. Stadlbauer U, Arnold M, Weber E, Langhans W. Possible mechanisms of circulating PYY-induced satiation in male rats. Endocrinology. 2013;154(1):193-204.
27. Flynn FW, Grill HJ. Fourth ventricular phlorizin dissociates feeding from hyperglycemia in rats. Brain Res. 1985;341(2):331.
28. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. New York, NY: Academic Press; 2007.
29. Ritter RC, Slusser PG, Stone S. Glucoreceptors controlling feeding and blood glucose: location in the hindbrain. Science. 1981; 213(4506):451-452.
30. Curtis KS, Sved AF, Verbalis JG, Stricker EM. Lithium chlorideinduced anorexia, but not conditioned taste aversions, in rats with area postrema lesions. Brain Res. 1994;663(1):30-37.
31. Curtis KS, Huang W, Sved AF, Verbalis JG, Stricker EM. Impaired osmoregulatory responses in rats with area postrema lesions. Am J Physiol. 1999;277(1 Pt 2):R209-R219.
32. Cox JE, Randich A. Enhancement of feeding suppression by PYY(3- 36) in rats with area postrema ablations. Peptides. 2004;25(6):985-989.
33. Surina-Baumgartner DM, Langhans W, Geary N. Hepatic portal insulin antibody infusion increases, but insulin does not alter, spontaneous meal size in rats. Am J Physiol. 1995;269(5 Pt 2):R978-R982.
34. Silberbauer CJ, Surina-Baumgartner DM, Arnold M, Langhans W. Prandial lactate infusion inhibits spontaneous feeding in rats. Am J Physiol Regul Integr Comp Physiol. 2000;278(3):R646-R653.
35. Porter MH, Arnold M, Langhans W. Lipopolysaccharide-induced anorexia following hepatic portal vein and vena cava administration. Physiol Behav. 1998;64(5):581-584.
36. Ackroff K, Sclafani A. Conditioned flavor preferences: evaluating postingestive reinforcement by nutrients. Curr Protoc Neurosci. 2001;Chapter 8:Unit 8.6F.
37. Arnold M, Langhans W. Effects of anesthesia and blood sampling techniques on plasma metabolites and corticosterone in the rat. Physiol Behav. 2010;99(5):592-598.
38. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65-70.
39. Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology. 2003;28(7):916-931.
40. Hayes MR, Bradley L, Grill HJ. Endogenous hindbrain glucagonlike peptide-1 receptor activation contributes to the control of food intake by Mediating Gastric Satiation Signaling. Endocrinology. 2009;150(6):2654-2659.
41. Yamamoto H, Kishi T, Lee CE, et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci. 2003;23(7):2939- 2946.
42. Woods SC, Langhans W. Inconsistencies in the assessment of food intake. Am J Physiol Endocrinol Metab. 2012;303(12):E1408-E1418.
43. Baraboi ED, Smith P, Ferguson AV, Richard D. Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist. Am J Physiol Regul Integr Comp Physiol. 2010; 298(4):R1098-R1110.
44. Labouesse MA, Stadlbauer U, Weber E, Arnold M, Langhans W, Pacheco-Ló pez G. Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4. J Neuroendocrinol. 2012;24(12):1505-1516.
45. Hayes MR, Kanoski SE, De Jonghe BC, et al. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1. Am J Physiol Regul Integr Comp Physiol. 2011;301(5):R1479-R1485.
46. Barrera JG, D'Alessio DA, Drucker DJ, Woods SC, Seeley RJ. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes. 2009;58(12):2820-2827.
47. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology. 2009;150(4):1680-1687.
48. Shapiro RE, Miselis RR. The central neural connections of the area postrema of the rat. J Comp Neurol. 1985;234(3):344-364.
49. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110(1): 43-52.
50. Hayes MR, Skibicka KP, Grill HJ. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology. 2008;149(8):4059-4068.
51. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes. 2008;57(8):2046-2054.
52. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience. 1997;77(1): 257-270.
53. Vrang N, Hansen M, Larsen PJ, Tang-Christensen M. Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei. Brain Res. 2007; 1149:118-126.
54. Trapp S, Hisadome K. Glucagon-like peptide 1 and the brain: Central actions- central sources? Auton Neurosci. 2011;161(1-2):14-19.
55. Schober G, Arnold M, Birtles S, et al. Diacylglycerol acyltransferase- 1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats. J Lipid Res. 2013;54(5):1369-1384.
56. Iritani N, Sugimoto T, Fukuda H, Komiya M, Ikeda H. Oral triacylglycerols regulate plasma glucagon-like peptide-1(7-36) and insulin levels in normal and especially in obese rats. J Nutr. 1999; 129(1):46-50.
57. Anini Y, Fu-Cheng X, Cuber JC, Kervran A, Chariot J, Roz C. Comparison of the postprandial release of peptide YY and proglucagon- derived peptides in the rat. Pflugers Arch. 1999;438(3):299-306.
58. Yoder SM, Yang Q, Kindel TL, Tso P. Stimulation of incretin secretion by dietary lipid: is it dose dependent? Am J Physiol Gastrointest Liver Physiol. 2009;297(2):G299-G305.
59. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept. 2005;128(2):117-124.
60. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993;138(1):159-166.
61. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion. 1995; 56(2):117-126.
62. Beglinger C, Degen L. Gastrointestinal satiety signals in humans- physiologic roles for GLP-1 and PYY? Physiol Behav. 2006;89(4): 460-464.
63. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36(11-12):761-765.
64. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7- 36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214(3):829-835.
65. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagonlike peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609-613.
66. Rhee NA, Vilsbøll T, Knop FK. Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes. Diabetes Obes Metab. 2012;14(4):291-298.
67. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
68. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(6):2719-2725.
69. Elahi D, McAloon-DykeM,Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 1994;51(1):63-74.
70. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011; 124(1 Suppl):S3-S18.